How to... IPO Series

Mar 29 2016https://www.eventbrite.com/e/how-to-ipo-series-tickets-20106147027

Join us for "How to... IPO", a 3 days program organized in partnership with West Deloitte Life Sciences practice:

Workshop 1 | Choose your exit: How to benefit from IPO preparation | March 29
Workshop 2 | IPO Readiness Bootcamp | April 20
Workshop 3 | Lessons Learned: The IPO process from field tested Veterans | May 19

As with all of our events, the "How to... IPO" is interactive and informal so bring your questions with you!


Workshop 1 | Choose your exit: How to benefit from IPO preparation | March 29

The business development professional's purpose is to optimize optionality and long term value at each stage of a company's life. As a company grows and gains traction, it's easy to get enticed and overwhelmed by the numerous opportunities that arise. How do you determine the direction that will add the most value to your company? How do you avoid the constant pursuit of "shiny objects?" How do you know when it's the right time for a strategic partnership?

At this event, you will learn how to prepare your company for IPO as well as the key differences between M&A and IPO exits. Key focus areas include:

  • What are the key decisions you need to make and when do you need to make them?
  • When is the right time to develop your exit strategy?
  • Key considerations and differences between M&A and IPO exits
  • Job Act requirements
  • SEC requirements for IPO and post IPO
  • Key stakeholders to manage through the IPO process
  • Company's internal processes pre- and post-IPO

Deloitte will share their experiences working with startup life sciences companies through the IPO process and beyond. The skills learned during this program are valuable to all young companies whether or not they eventually go through an IPO. This workshop is geared towards life sciences startups.

Agenda:
12:00 PM | Registration Opens, Lunch and Networking
12:40 PM | Life sciences company - life events
1:10 PM | Financing strategies
1:30 PM | Exit strategy: M&A vs. IPO
1:50 PM | IPO requirements - Job Act
2:20 PM | Coffee Break
2:30 PM | Ready for IPO?
3:00 PM | Going through the IPO process
3:30 PM | Company post IPO
3:50 PM | Next events: IPO readiness bootcamp; Lessons learned
4:00 PM | Program Close

Speakers:
Matthew Hudes | US Managing Principal, Biotechnology, Deloitte Consulting LLP read bio»
Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP read bio»
Bruce Gribens | Tax Partner, M&A Transaction Services, Deloitte Tax LLP read bio»
Alan Warner | Deloitte Advisory Partner, Mergers, Acquisitions & Divestitures, Deloitte & Touche LLP read bio»

Location:
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, CA

Workshop 1 Fees:
$30 | General Public
$45 | At the door

Speakers' Biographies:

Matthew Hudes | US Managing Principal, Biotechnology, Deloitte Consulting LLP
Matthew is the BioPharma segment leader for Deloitte's Life Sciences practice sector. He speaks frequently about such topics as fostering innovation, personalized medicine, the use of technology for innovating clinical research, finance transformation, manufacturing and quality, regulatory compliance, and supply chain. Matthew is the executive sponsor of Deloitte's unique innovation collaboration with the University of California, and is the Lead Client Service Principal for the California Institute for Quantitative Biosciences (QB3). He is a member of the Board of Directors of BIOCOM and of the Bay Area BioEconomy Initiative, and a faculty member and executive sponsor of the UC Berkeley BioExec Institute.
Connect with Matthew: Connect on LinkedIn



Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.
Connect with Angela: Connect on LinkedIn



Bruce Gribens | Tax Partner, M&A Transaction Services, Deloitte Tax LLP
Bruce has more than twenty-four years of professional experience in public accounting, specializing in corporate organizations and restructurings, as well as tax controversy and tax shelter compliance. Bruce spent four years in the subchapter C group in the Firm's Washington National Tax office and led the Firm's Central Sector's Tax Controversy Services group for three years. During the past 10 years, Bruce has served leading private equity investment firms and corporate acquirors / sellers in structuring acquisitions / dispositions and performing due diligence reviews. Currently, Bruce co-leads Deloitte's service line for Seller Dilgence Services in the US. Before San Francisco, Bruce spent five years in Boston as part of the lead tax services team; two years in Washington National Tax and three years in Omaha directing the Tax Controversy Services group; and five years in Washington, DC and Northern Virginia providing technical advice to the firm's largest clients related to their corporate restructurings, including taxable and tax-free asset and stock acquisitions; dispositions of subsidiaries and unwanted assets; debt work-outs; tax-free spin-offs; cancellation of indebtedness; net operating loss planning; and capitalization versus expense analysis.
Connect with Bruce: Connect on LinkedIn



Alan Warner, CPA| Deloitte Advisory Partner, Mergers, Acquisitions & Divestitures, Deloitte & Touche LLP
Alan is a Deloitte Advisory Partner in San Francisco and a leader within the Mergers, Acquisitions & Divestitures practice. Deloitte's M&A practice is a cross functional team of accounting, tax, consulting and financial risk advisory professionals dedicated to serving the unique needs of clients undergoing merger, acquisition and divestiture transactions. Alan is an accountant and his primary role on M&A engagements is to assist clients with financial due diligence and other transaction execution services on both the buy-side and the sell-side. Alan has supported his clients with hundreds of M&A transactions over the course of his career including multi-billion dollar strategic mergers, all manner of LBOs and deep expertise in advising on complex, cross border carve-out transactions. His experiences include major transactions with many of the Firm's leading private equity clients (including Blackstone, Hellman & Friedman, Silver Lake, Thoma Bravo and TPG) as well as advising on M&A deals for the likes of Coca Cola, the Gap, McKesson, Nokia, Sony, Starbucks and Wal-Mart. Alan currently serves as the West Coast co-leader of Deloitte Advisory's divestiture services initiative which supports organizations with all financial related aspects of divestitures, spin-offs and line of business / division sales. Primary services include assistance with the preparation of carve-out financial statements, seller due diligence, quality of earnings analyses and other seller transaction execution services.
Connect with Alan: Connect on LinkedIn




Workshop 2 | IPO Readiness Bootcamp | April 20

Are you on IPO watch? Whether IPO starts are up or down, and they will be up and down, the most important time for your company to be IPO ready is now. Expertise learned by being IPO ready benefits your firm regardless of your final go/ no-go IPO decision. Join us for the ultimate IPO crash course to learn directly from the pros.

There are many stakeholders to manage when you prepare your company for an IPO exit, including your investors, bankers, attorneys, auditors and insurance advisors. We invited them all to share their insights, real stories, case studies and to answer your pressing questions. Don't miss this opportunity to enhance your knowledge and understanding of the step by step IPO process during our day-long program.

The Bootcamp features small group sessions with investment bankers, attorneys, insurance and auditors/tax professionals to provide focus on individual needs. Through direct interactions with these professionals, you will become confident in building your IPO readiness plan as well as learn from group member experiences and questions.

Key questions about preparing for the IPO process through IPO pricing and closing will be answered including:

  • When and how to start IPO readiness process?
  • Are your investors and internal processes ready for the IPO?
  • Who from your company will be involved in the process and how much time does it take?
  • How to manage your relationships with auditors during the process and what to expect and when?
  • When and how to engage and choose your bankers?
  • What to expect from banker's due diligence?
  • IPO process detailed steps and timing
  • Registration statement drafting - who is involved, how long does it take, what it includes and who will help with draft creation?
  • SEC review process of the registration statement
  • Roadshow - how to be best prepared for it?
  • IPO pricing and IPO closing - who is involved and what are their roles?
  • What do you need to know about D&O insurance? - Who sues you, and for what, as a public company?
  • What are three pillars of protection to mitigate D&O risk?
  • What is the timeline for D&O Insurance for an IPO, including what are private companies' transition issues?

Also, bring your own questions to receive direct, practical responses from our group of professional advisors. The more you know, the better prepared your internal resources and processes are to meet IPO challenges. After this program, you will be equipped to build stronger and more efficient relationships with all stakeholders, improve your IPO plan and more efficiently manage your IPO costs.

2016 Global sciences outlook: Moving forward with cautious optimism

Agenda:
Event starts at Genentech Hall / Byers Auditorium
8:00 AM | Registration, Networking and Breakfast
9:00 AM | Welcome and Event introduction
Move to Mission Hall / Assigned rooms
9:40 AM | Get to your breakouts
9:50 AM | Breakout 1
10:50 AM | Get to your breakouts
11:00 AM | Breakout 2
12:00 PM | Lunch
12:50 PM | Breakout 3
1:50 PM | Coffee Break
2:00 PM | Get to your breakouts
2:10 PM Breakout 4
3:15 PM | Q&A Panel
3:45 PM | Program Close

Facilitators:
Guest Speaker:
Laura Brege | Managing Director, Cervantes Life Science Partners read bio»
Investment Bankers:
Joshua House | Vice President, Citigroup's Health Care Investment Banking Group read bio»
Nick Jennings | Senior Associate , Citigroup's Health Care Investment Banking Group read bio»
Attorneys:
Michael Tenta | Partner, Cooley LLP read bio»
Carlton Fleming | Associate, Cooley LLP read bio»
D&O Insurance:
Steve Sawyer | Partner & Executive Vice President, Woodruff-Sawyer &Co read bio»
Priya Cherian Huskins | Partner & Senior Vice President, Woodruff-Sawyer &Co read bio»
Auditors:
Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP read bio»
Jason Richter | National Federal Tax Services Transaction & Integration Services, Deloitte Tax LLP read bio»
David Lyness | Director, Deloitte Tax Services read bio»

Locations:
UCSF Genentech Hall / Byers Auditorium: 600 16th St, San Francisco, CA
UCSF Mission Hall: 1599 4th St, San Francisco, CA

Workshop 2 Fees:
$65 | General Public (limited availability)
No Onsite Registration!

Speakers' Biographies:

Laura Brege | Managing Director, Cervantes Life Science Partners
Laura Brege has over 25 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Most recently, Ms. Brege was President & CEO of Nodality, Inc., a private company focused on innovative personalized medicine approaches in oncology, immunology and immuno-oncology. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a global oncology company, including Executive Vice President and Chief Operating Officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, technical operations and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm investing in early stage technology companies. Previously Ms. Brege was CFO at COR Therapeutics, helping build the company from an early stage R&D company through commercial launch of a successful cardiovascular product. Earlier she served as CFO at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege serves on the Board of Directors of Acadia Pharmaceuticals, Aratana Therapeutics, Dynavax Technologies, Portola Pharmaceuticals and Pacira Pharmaceuticals. She served on the Board of California Life Sciences Association (CLSA). Ms. Brege received her MBA from The University of Chicago and her undergraduate degree from Ohio University, Honors Tutorial College.



Joshua House | Vice President, Citigroup's Health Care Investment Banking Group
Josh House is a Vice President in the San Francisco office of Citi’s Healthcare Investment Banking group. His practice focuses mainly on life sciences companies and spans equity, debt and M&A advisory. He has been with Citi since 2013; prior to that he was a practicing tax and M&A attorney in the San Francisco office of Latham & Watkins. He holds a JD/MBA from Columbia and a BA from Stanford.



Nick Jennings | Senior Associate , Citigroup's Health Care Investment Banking Group
Nick Jennings is a Senior Associate in the San Francisco office of Citi’s Healthcare Investment Banking group. His practice covers life sciences and medical technology companies and spans equity, debt and M&A advisory. He has been with Citi since 2013; prior to that he was in the Equity Capital Markets groups at BofA Merrill Lynch and Stifel Nicolaus Weisel. He holds an MBA from UC Berkeley and a BS in Chemical Engineering from Columbia.



Michael Tenta | Partner, Cooley LLP
Michael E. Tenta is a partner in the Cooley Business department. He joined the Firm in 2000 and is resident in the Palo Alto office. Mr. Tenta practices corporate and securities law, representing public and private companies, investors and investment banks in a variety of matters, including securities offerings, mergers and acquisitions, and general corporate and commercial law. Prior to joining Cooley, Mr. Tenta was an associate at the law firm of Lawson Lundell in Vancouver, Canada, where he advised both public and private companies in the technology, manufacturing and resource sectors. Mr. Tenta graduated from the University of Victoria Faculty of Law in 1997. During his legal studies, he spent a term working at the Intellectual Property Policy Directorate of the Government of Canada and at the University of the South Pacific Department of Law. Mr. Tenta graduated from Simon Fraser University with a BS (Biology) in 1993. Mr. Tenta is a member of the State Bar of California, the American Bar Association and the Law Society of British Columbia. Mr. Tenta is not admitted to practice in Washington state.



Carlton Fleming | Associate, Cooley LLP
Carlton Fleming is an associate in Cooley's Business department and a member of the Public Companies, Capital Markets and Emerging Companies practice groups. He joined the Firm in 2012 and is resident in the Palo Alto office. Carlton practices general corporate and securities law, representing both public and private companies in a wide range of matters, including formation and financing activities, SEC reporting and compliance, corporate governance and mergers and acquisitions. He also represents investment banks and venture capital firms in public offerings and private placements of equity and debt securities. Since 2012, Carlton has been involved in over 25 IPOs and other public offerings, raising over $3 billion. Carlton received a JD and an LLM in International and Comparative Law in 2007 from Duke University School of Law. He received a BA in German and History in 2004 from Duke University. Mr. Fleming is a member of the State Bar of California and the State Bar of North Carolina.



Steve Sawyer | Partner & Executive Vice President, Woodruff-Sawyer &Co
A trusted advisor to Silicon Valley companies and beyond, Steve's creativity and passion for solving clients' most complex risk challenges has led him to become an industry innovator. Steve has been partnering with technology and life sciences clients since joining the firm in 1981. He launched its Life Sciences Practice in 1991—today one of the nation's largest. Under Steve's leadership, Woodruff-Sawyer as the Biotechnology Industry Organization's (BIO's) as its West Coast risk management partner. Steve works with organizations from new venture formation through IPO, commercialization and international expansion. In addition to P&C, he has extensive experience addressing D&O liability needs of public company clients. Steve also founded Woodruff-Sawyer's CleanTech Practice in 2008. He worked with global insurers to create innovative Performance Warranty programs for solar and other clean tech projects, providing customized financial backstops to facilitate "bankability" for securing financing for various projects. Steve is on Woodruff-Sawyer's Board of Directors and has served on the board for BayBio, the biotechnology trade organization for Northern California. He is active in various non-profits and missions committed to pressing needs in our community and around the world. Steve has a bachelor's degree from Stanford University and an MBA from Northwestern University's Kellogg Graduate School of Management. He is a designated Chartered Property and Casualty Underwriter (CPCU).



Priya Cherian Huskins, Esq. | Partner & Senior Vice President, Woodruff-Sawyer &Co
Priya Cherian Huskins is a recognized expert in D&O liability risk and its mitigation. In addition to consulting on D&O insurance matters, she counsels clients on corporate governance matters, including ways to reduce their exposure to shareholder lawsuits and regulatory investigations. Priya is a frequent speaker on D&O issues and a regular guest lecturer at Stanford's Directors' College, among others. She is also the author of the D&O Notebook, a blog that monitors, curates and summarizes issues as they arise in the areas of D&O liability, insurance and corporate governance. Priya serves on the board of directors of Realty Income Corporation (NYSE: O) as well as the Advisory Board for the Stanford University Rock Center for Corporate Governance. Priya is also on the board of the of the Silicon Valley Directors' Exchange (SVDX). Priya was listed as one of the "Most Influential Women in Bay Area Business" by the San Francisco Business Times in 2012. She was a judge for the prestigious Ernst & Young Entrepreneur of the Year award in Northern California from 2009-2011. Priya was named one of the "Top 100 Women of Influence in the Silicon Valley" in 2009 by the San Jose/Silicon Valley Business Journal. Prior to joining Woodruff-Sawyer, Priya practiced corporate and securities law at Wilson Sonsini Goodrich & Rosati. Priya has worked with both public and private technology companies through all stages of their development. Priya was awarded her juris doctorate with honors from the Law School at the University of Chicago. She earned her undergraduate degree with high honors from Harvard University. Priya is a member of the California Bar.



Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.
Connect with Angela: Connect on LinkedIn



Jason Richter | National Federal Tax Services Transaction & Integration Services, Deloitte Tax LLP
Jason is a Senior Manager with National Federal Tax Services (Transaction & Integration Services), Deloitte Tax LLP, and has over 14 years of professional experience specializing in corporate tax matters including merger and acquisition related due diligence, tax structuring, and tax modeling. Jason is primarily involved in providing Section 382 and NOL consulting services including the day to day management of the preparation of full Section 382 ownership change studies and the computation of the related annual limitations. Jason is also responsible for the preparation and review of quarterly Section 382 update analyses and the review of studies in support of tax return preparation and financial statement reporting and disclosure. Jason is frequently involved in providing Section 382 services as part of due diligence for merger and acquisition transactions as well as NOL planning and structuring. He serves a variety of public and private company clients. Jason has been providing Section 382 services for over eleven years, authored several articles in this area, and has appeared as a guest lecturer on the topic.



David Lyness | Director, Deloitte Tax Services
David leads Deloitte's Silicon Valley R&D tax credit practice. Over the past 20 years, David has specialized in serving life science and other technology companies. Primary focus areas include developing R&D tax credit claims and representing clients before the IRS and state tax authorities. David is a member of the New York Bar, and has degrees in accounting and law, including an LL.M (Tax) from New York University School of Law.




Workshop 3 | Lessons Learned: The IPO process from field tested Veterans | May 19

There is nothing like experience! The final event in our 3 part IPO series with Deloitte & Touche, LLP brings in two high profile C-level executives. They have gone through the IPO experience and as IPO journey's go, their paths were different.

This breakfast event will take a look at two companies that recently went through successful IPO's. The company leaders will share their insights from firsthand experience on issues ranging from preparation to execution.

Topics include:

  • Hiring the right professional team
  • Managing the Board
  • The roadshow
  • Pricing, timing and market conditions
  • The surprises, pitfalls and lessons learned
  • With plenty of time for Q&A

Join us for an insider's look at the IPO!

Agenda:
8:15 AM | Registration Opens, Breakfast and Networking
9:00 AM | Panel and Q&A
10:30 AM | Closing remarks and networking
11:00 AM | Program Close

Speakers:
Jennifer Lew | Senior Vice President of Finance, Aduro Biotech read bio»
Isaac Ciechanover | President & CEO, Atara Biotherapeutics read bio»
[moderator] Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP read bio»

Location:
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, CA

Workshop 3 Fees:
$20 | General Public
$35 | At the door

Speakers' Biographies:

Jennifer Lew | Senior Vice President of Finance, Aduro Biotech
Jennifer Lew joined Aduro in October 2013 and has served as our Senior Vice President of Finance since January 2015. Prior to joining Aduro, Ms. Lew held various roles at Dynavax Technologies Corporation, a biopharmaceutical company, from 2004 to October 2013, most recently as Vice President of Finance and Principal Accounting Officer, where she oversaw accounting and finance operations. Prior to joining Dynavax, Ms. Lew held positions as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, from 2000 to 2004. Ms. Lew was a member of the audit practice at Ernst & Young from 1994 to 1999. She earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).



Isaac Ciechanover, M.D. | President & CEO, Atara Biotherapeutics
Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in August 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene's Executive Director for Business Development, he spearheaded the company's venture capital efforts and led licensing and M&A activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was Global Project Leader for the company's first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures' healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd's "The Dark Side of the Moon," Radiohead's "OK Computer" and Ruggero Leoncavallo's Italian opera, Pagliacci, with Herbet Von Karajan conducting.



Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.
Connect with Angela: Connect on LinkedIn




About Deloitte
Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that have helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams.

Share